Case Report Review Synthesis: Cyclic Neutropenia Response to rhG-CSF in a Pediatric Patient

This document functions as a review and synthesis based on a single case report involving a pediatric population. The scope focuses on the management of cyclic neutropenia, specifically examining the clinical course of a 7-year-old girl. The evidence level is identified as a case report, indicating preliminary observations rather than controlled trial data.

The intervention involved the administration of recombinant human granulocyte colony-stimulating factor combined with infection control and supportive care. The patient responded well to this treatment regimen. Follow-up duration is noted as awaiting hematopoietic stem cell transplantation (HSCT), meaning long-term outcomes remain pending. No specific adverse events or discontinuations were reported in the available data.

Authors note significant limitations regarding the generalizability of these findings to broader populations. The certainty of the evidence is low due to the single-case design. There is a caution against inferring causality beyond the specific instance of a de novo ELANE c.416C>T mutation causing cyclic neutropenia. Safety data regarding adverse events were not reported. Consequently, clinical application requires careful consideration of individual patient factors.

Practice relevance emphasizes that early and accurate diagnosis, individualized treatment, and long-term follow-up are critical to improve outcomes. Clinicians should interpret these results with caution given the observational nature of the evidence. The synthesis highlights the potential utility of rhG-CSF in this specific context while acknowledging the need for further investigation. Monitoring for response and safety remains essential during the treatment period.